406 related articles for article (PubMed ID: 23429668)
21. Hepatotropic viruses: new insights in pathogenesis and treatment.
Gatta A; Giannini C; Lampertico P; Pontisso P; Quarta S; Zignego AL; Atzeni F; Sarzi-Puttini P
Clin Exp Rheumatol; 2008; 26(1 Suppl 48):S33-8. PubMed ID: 18570752
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
Haddad JG; Rouillé Y; Hanoulle X; Descamps V; Hamze M; Dabboussi F; Baumert TF; Duverlie G; Lavie M; Dubuisson J
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179528
[TBL] [Abstract][Full Text] [Related]
23. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
[TBL] [Abstract][Full Text] [Related]
25. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance.
Fukuda R; Ishimura N; Niigaki M; Hamamoto S; Satoh S; Tanaka S; Kushiyama Y; Uchida Y; Ihihara S; Akagi S; Watanabe M; Kinoshita Y
J Med Virol; 1999 Jul; 58(3):201-7. PubMed ID: 10447413
[TBL] [Abstract][Full Text] [Related]
26. Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.
Douam F; Bobay LM; Maurin G; Fresquet J; Calland N; Maisse C; Durand T; Cosset FL; Féray C; Lavillette D
J Virol; 2016 Jan; 90(2):992-1008. PubMed ID: 26537674
[TBL] [Abstract][Full Text] [Related]
27. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
28. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients.
Igaki N; Nakaji M; Moriguchi R; Akiyama H; Tamada F; Oimomi M; Goto T
J Gastroenterol; 2003; 38(10):968-76. PubMed ID: 14614604
[TBL] [Abstract][Full Text] [Related]
29. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
Spaan M; Bruce M; Agarwal K; Carey I
Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
[TBL] [Abstract][Full Text] [Related]
30. Quantification and genotyping in management of chronic hepatitis B and C.
Zoulim F
Virus Res; 2002 Jan; 82(1-2):45-52. PubMed ID: 11885949
[No Abstract] [Full Text] [Related]
31. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
32. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
33. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
[TBL] [Abstract][Full Text] [Related]
34. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Kırdar S; Yaşa MH; Sayan M; Aydın N
Mikrobiyol Bul; 2019 Apr; 53(2):144-155. PubMed ID: 31130119
[TBL] [Abstract][Full Text] [Related]
35. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.
Pollicino T; Amaddeo G; Restuccia A; Raffa G; Alibrandi A; Cutroneo G; Favaloro A; Maimone S; Squadrito G; Raimondo G
Hepatology; 2012 Aug; 56(2):434-43. PubMed ID: 22271491
[TBL] [Abstract][Full Text] [Related]
36. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.
Serre SB; Krarup HB; Bukh J; Gottwein JM
J Virol; 2013 Dec; 87(23):12776-93. PubMed ID: 24049176
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.
Zhu W; Wu C; Deng W; Pei R; Wang Y; Cao L; Qin B; Lu M; Chen X
PLoS One; 2012; 7(9):e45146. PubMed ID: 23024803
[TBL] [Abstract][Full Text] [Related]
38. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.
Zhao Y; Ren Y; Zhang X; Zhao P; Tao W; Zhong J; Li Q; Zhang XL
J Immunol; 2014 Jul; 193(2):783-96. PubMed ID: 24928988
[TBL] [Abstract][Full Text] [Related]
39. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.
Douam F; Dao Thi VL; Maurin G; Fresquet J; Mompelat D; Zeisel MB; Baumert TF; Cosset FL; Lavillette D
Hepatology; 2014 Mar; 59(3):776-88. PubMed ID: 24038151
[TBL] [Abstract][Full Text] [Related]
40. [Monitoring patients with chronic hepatitis during and after therapy].
Colić-Cvrlje V; Mise S
Acta Med Croatica; 2009 Dec; 63(5):377-83. PubMed ID: 20198895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
